Shionogi/ViiV's HIV integrase inhibitor set for Phase III trials
This article was originally published in Scrip
Executive Summary
The Shionogi/ViiV Healthcare joint venture for HIV drug research plans to take its lead drug candidate – the oral integrase inhibitor, S/GSK1349572 ('572) –into Phase III trials by the end of the year.